Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

Aptevo Therapeutics Inc APVO stock is surging on Wednesday.As per data from Benzinga Pro, the stock is trading higher with a strong volume of 81.8 million compared to the average volume of 275.3k.What Happened: Aptevo revealed new clinical data from its ongoing Phase 1b/2 RAINIER trial evaluating mipletamig, its first-in-class CD123 x CD3 bispecific antibody, in combination with standard-of-care venetoclax and azacitidine (ven/aza) for newly diagnosed patients with acute myeloid leukemia (AML) who are unfit ...